Clonazepam 0.25 mg + Paroxetine HCL 12.5 mg Tablets
RUPATINE-CR LS is a low-strength psychiatric combination tablet having Clonazepam 0.25 mg and Paroxetine Hydrochloride (Controlled Release) 12.5 mg in a single tablet under the Eridanus Healthcare range of products. The mechanism involved is the combination of both the fast-acting anxiolytic and soothing effect of Clonazepam (benzodiazepine drug) and the long-lasting antidepressant and anxiolytic effect of Paroxetine CR (SSRI drug), giving a dual action of management of anxiety and depression right from the first dose itself. The “LS” indicates the lower starting doses, which make it ideal for starting off therapy in treatment-naïve patients, older patients and those needing dose escalation.
This drug from Eridanus Healthcare is available through their exclusive Neuro/Psychiatry PCD Pharma Franchise distribution channel and is available in 10x10 Alu-Alu blister packaging.
Uses and Indications
RUPATINE-CR LS is used by psychiatrists for the initiation and treatment of:
- Anxiety Disorders – Generalised Anxiety Disorder (GAD), Social Anxiety Disorder, and Panic Disorder upon initiating treatment
- Major Depressive Disorder (MDD) in conjunction with anxiety symptoms needing immediate anxiolytic bridging therapy
- Mixed anxiety-depressive disorder wherein the need is for both anxiolytic and antidepressant actions to be effective together
- Panic Disorder – the Clonazepam part of the medication provides quick relief from panic while the Paroxetine component gets its antidepressant effect built up
- Obsessive-Compulsive Disorder (OCD) having high anxiety where both short-term relief from symptoms and long-term SSRIs are needed
- Initiating antidepressant therapy in elderly or sensitive patients who may need lower initial doses
- Bridging anxiolytic therapy in the short term for 2-4 weeks till Paroxetine builds up its antidepressant action
How do Clonazepam 0.25 mg + Paroxetine HCL 12.5 mg Tablets Work?
RUPATINE-CR LS consists of two different and complementary mechanisms of action. Clonazepam is a long-acting drug belonging to the class of benzodiazepines, which potentiates the action of gamma-aminobutyric acid (GABA), the main inhibitory neurotransmitter in the central nervous system, through binding with GABA-A receptors and increasing the opening frequency of chloride ion channels. As a result, anxiolytic, sedative and anticonvulsant action develops in 30-60 minutes after administration. Paroxetine Hydrochloride CR is a strong SSRI, which blocks the serotonin reuptake process, providing increased levels of serotonin in the synaptic cleft for 2-4 weeks of its use as a medication.
PCD Pharma Franchise for Clonazepam 0.25 mg + Paroxetine HCL 12.5 mg Tablets
Eridanus Healthcare is a speciality pharmacy in neuro/psychiatry providing a unique range of prescription drugs in Anti-Depressants, Anti-Anxiety, CNS & Neurological Disorders, Psychiatry, Neurological Pain, and related specialities. We are extending an invitation to all pharma professionals, medical representatives, and distributors in India to join hands with us in obtaining the PCD Pharma Franchise and Monopoly Distribution rights for RUPATINE-CR LS and the entire range of Eridanus Neuro/Psychiatry products.
Why Choose Eridanus Healthcare for Neuro PCD Pharma Franchise?
- Monopoly-based PCD Pharma Franchise for RUPATINE-CR LS and the full Eridanus Neuro/Psychiatry range in your district/state
- Speciality neuro/psychiatry range –Anti-Depressants, Anti-Anxiety, Anti-Psychotics, CNS, Neurological Pain, and Nutritional products
- High margin with competitive net rates and clear MRP
- WHO-GMP certified manufacturing
- Free marketing material –visual aids, MR bag, sample kits, reminder card, and product literature
- Timely order processing and efficient pan-India logistics
- Expert franchise support for business onboarding and other business support
- Expanding market of neuro/psychiatry with increasing awareness and prescriptions in India